

# Nuvalent to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

CAMBRIDGE, Mass., Feb. 5, 2026 /PRNewswire/ -- [Nuvalent, Inc.](#) (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D., Chief Executive Officer, and Alexandra Balcom, Chief Financial Officer, will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026, at 1:30 p.m. ET in NYC.

A live webcast will be available in the Investors section of Nuvalent's website at [www.nuvalent.com](http://www.nuvalent.com), and archived for 30 days following the presentation.

## About Nuvalent

Nuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creating *precisely* targeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.

SOURCE Nuvalent, Inc.

## Investor Contact:

Chelcie Lister  
Nuvalent, Inc.  
[clister@nuvalent.com](mailto:clister@nuvalent.com)

## Media Contact:

Josie Butler  
1AB  
[josie@1abmedia.com](mailto:josie@1abmedia.com)

---

<https://investors.nuvalent.com/2026-02-05-Nuvalent-to-Participate-in-the-Guggenheim-Emerging-Outlook-Biotech-Summit-2026>